Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,785,388
  • Shares Outstanding, K 150,676
  • Annual Sales, $ 10,900 K
  • Annual Income, $ -322,300 K
  • EBIT $ -612 M
  • EBITDA $ -631 M
  • 60-Month Beta 0.90
  • Price/Sales 989.20
  • Price/Cash Flow N/A
  • Price/Book 5.53

Options Overview Details

View History
  • Implied Volatility 14.27% (-0.13%)
  • Historical Volatility 100.57%
  • IV Percentile 10%
  • IV Rank 7.57%
  • IV High 121.12% on 07/14/25
  • IV Low 5.52% on 10/31/25
  • Expected Move (DTE 14) 1.74 (2.44%)
  • Put/Call Vol Ratio 3.66
  • Today's Volume 191
  • Volume Avg (30-Day) 1,248
  • Put/Call OI Ratio 1.88
  • Today's Open Interest 63,625
  • Open Int (30-Day) 58,979
  • Expected Range 69.80 to 73.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.11
  • Number of Estimates 5
  • High Estimate -0.61
  • Low Estimate -1.41
  • Prior Year -0.80
  • Growth Rate Est. (year over year) -38.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.67 +2.68%
on 11/07/25
71.78 -0.33%
on 11/28/25
+1.71 (+2.45%)
since 11/04/25
3-Month
35.70 +100.39%
on 09/11/25
71.78 -0.33%
on 11/28/25
+23.07 (+47.60%)
since 09/04/25
52-Week
21.51 +232.59%
on 04/09/25
71.78 -0.33%
on 11/28/25
+33.61 (+88.61%)
since 12/04/24

Most Recent Stories

More News
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 13.12 (+0.23%)
TCBX : 38.96 (-0.31%)
RNA : 71.54 (-0.06%)
FSUN : 35.08 (+1.24%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

ATXS : 13.12 (+0.23%)
TCBX : 38.96 (-0.31%)
RNA : 71.54 (-0.06%)
FSUN : 35.08 (+1.24%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

TCBX : 38.96 (-0.31%)
RNA : 71.54 (-0.06%)
FIZN : 76.0000 (+18.66%)
WTRG : 37.90 (-2.47%)
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...

RNA : 71.54 (-0.06%)
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company...

RNA : 71.54 (-0.06%)
Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

RNA : 71.54 (-0.06%)
PLYM : 21.91 (-0.32%)
WTRG : 37.90 (-2.47%)
Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

JAMF : 12.96 (-0.08%)
RNA : 71.54 (-0.06%)
AWK : 128.93 (-1.56%)
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis....

RNA : 71.54 (-0.06%)
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

RNA : 71.54 (-0.06%)
S&P Futures Muted After Record Rally, FOMC Meeting and Earnings in Focus

December S&P 500 E-Mini futures (ESZ25) are trending down -0.02% this morning, taking a breather after a record-breaking rally, while investors await the start of the Federal Reserve’s two-day policy...

PYPL : 61.73 (+0.80%)
NVDA : 183.38 (+2.11%)
NOVN.Z.IX : 106.900 (-0.47%)
MP : 61.80 (+5.26%)
RNA : 71.54 (-0.06%)
BNP.FP : 75.690 (+1.94%)
NXPI : 226.16 (-0.62%)
USAR : 17.48 (+24.68%)
RMBS : 98.81 (+0.80%)
CAP.FP : 142.700 (+4.16%)
UNH : 333.49 (-1.83%)
NDX1.D.DX : 25.960 (+1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the...

See More

Key Turning Points

3rd Resistance Point 71.95
2nd Resistance Point 71.82
1st Resistance Point 71.68
Last Price 71.54
1st Support Level 71.41
2nd Support Level 71.28
3rd Support Level 71.14

See More

52-Week High 71.78
Last Price 71.54
Fibonacci 61.8% 52.58
Fibonacci 50% 46.65
Fibonacci 38.2% 40.71
52-Week Low 21.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar